Inter-observer agreement for Crohn's disease sub-phenotypes using the Montreal Classification: How good are we? A multi-centre Australasian study

Abstract

IOA using MC is generally good; however some areas are less consistent than others. Omissions and inaccuracies reduce the value of clinical data when comparing cohorts across different centres, and may impair the ability to translate genetic discoveries into clinical practice.

Never underestimate inflammatory bowel disease: High prevalence rates and confirmation of high incidence rates in Australia

“…This issue was recently highlighted in a paper published on variability in disease location definition. 25 The current study allowed reassessment of local IBD incidence rates. Using robust population-based multiple-source capture methodology, we demonstrated no significant change in local incidence rates from August 2007.…”

“…Variations in differentiating L1 from L3 disease, particularly when the colonic disease is limited to the caecum, may be a factor in this observation. This issue was recently highlighted in a paper published on variability in disease location definition …”

East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort

“…The age limit of 15 years was the referral age and was decided on by agreement between all centres. Disease phenotype classification by disease extent for UC, as well as disease location and behaviour for CD, were defined according to the Montreal classification10 which has previously been shown to have overall good interobserver agreement 11 12…”

Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study

“…Patients with CD refractory to conventional therapy have been able to access either infliximab (since 2007) or adalimumab (since 2008) through government‐funded schemes within Australia and in New Zealand. Nine hospitals within the ANZ IBD Consortium, and each with a dedicated IBD team, took part in the study. Consecutive patients at each centre with a confirmed diagnosis of CD based upon established criteria, and who had successfully applied to receive scheduled anti‐TNF therapy with either infliximab or adalimumab were included.…”